TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
TWD 8.97
(-7.33%)
TWD 8.97
(-7.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 110.94 Million TWD | 44.12% |
| 2022 | 76.97 Million TWD | -44.66% |
| 2021 | 139.11 Million TWD | 21.75% |
| 2020 | 114.26 Million TWD | -12.72% |
| 2019 | 130.92 Million TWD | 38.75% |
| 2018 | 94.35 Million TWD | -3.43% |
| 2017 | 97.7 Million TWD | -33.9% |
| 2016 | 147.82 Million TWD | -19.6% |
| 2015 | 183.85 Million TWD | -25.28% |
| 2014 | 246.05 Million TWD | -26.05% |
| 2013 | 332.71 Million TWD | -7.87% |
| 2012 | 361.14 Million TWD | 271.12% |
| 2011 | 97.31 Million TWD | -98.2% |
| 2010 | 5.4 Billion TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 112.74 Million TWD | 8.52% |
| 2024 Q1 | 103.89 Million TWD | -6.35% |
| 2023 Q3 | 118.63 Million TWD | -0.73% |
| 2023 Q4 | 110.94 Million TWD | -6.48% |
| 2023 FY | 110.94 Million TWD | 44.12% |
| 2023 Q1 | 83.95 Million TWD | 9.06% |
| 2023 Q2 | 119.5 Million TWD | 42.35% |
| 2022 Q1 | 96.87 Million TWD | -30.36% |
| 2022 FY | 76.97 Million TWD | -44.66% |
| 2022 Q4 | 76.97 Million TWD | -17.15% |
| 2022 Q2 | 109.83 Million TWD | 13.38% |
| 2022 Q3 | 92.9 Million TWD | -15.41% |
| 2021 Q3 | 61.31 Million TWD | -13.19% |
| 2021 Q4 | 139.11 Million TWD | 126.9% |
| 2021 Q1 | 51.29 Million TWD | -55.11% |
| 2021 Q2 | 70.62 Million TWD | 37.69% |
| 2021 FY | 139.11 Million TWD | 21.75% |
| 2020 Q2 | 73.9 Million TWD | -4.0% |
| 2020 Q1 | 76.98 Million TWD | -41.2% |
| 2020 Q3 | 66.01 Million TWD | -10.68% |
| 2020 FY | 114.26 Million TWD | -12.72% |
| 2020 Q4 | 114.26 Million TWD | 73.1% |
| 2019 Q1 | 176.01 Million TWD | 86.54% |
| 2019 Q4 | 130.92 Million TWD | 0.68% |
| 2019 FY | 130.92 Million TWD | 38.75% |
| 2019 Q3 | 130.03 Million TWD | -28.96% |
| 2019 Q2 | 183.04 Million TWD | 4.0% |
| 2018 Q4 | 94.35 Million TWD | 8.18% |
| 2018 FY | 94.35 Million TWD | -3.43% |
| 2018 Q3 | 87.22 Million TWD | 13.97% |
| 2018 Q2 | 76.53 Million TWD | 1.94% |
| 2018 Q1 | 75.07 Million TWD | -23.16% |
| 2017 FY | 97.7 Million TWD | -33.9% |
| 2017 Q2 | 98.24 Million TWD | -86.25% |
| 2017 Q3 | 104.87 Million TWD | 6.74% |
| 2017 Q4 | 97.7 Million TWD | -6.83% |
| 2017 Q1 | 714.52 Million TWD | 383.36% |
| 2016 FY | 147.82 Million TWD | -19.6% |
| 2016 Q4 | 147.82 Million TWD | 18.5% |
| 2016 Q3 | 124.75 Million TWD | -11.57% |
| 2016 Q2 | 141.08 Million TWD | -6.64% |
| 2016 Q1 | 151.1 Million TWD | -17.81% |
| 2015 Q2 | 190.48 Million TWD | -7.03% |
| 2015 FY | 183.85 Million TWD | -25.28% |
| 2015 Q4 | 183.85 Million TWD | -3.18% |
| 2015 Q3 | 189.88 Million TWD | -0.31% |
| 2015 Q1 | 204.89 Million TWD | -16.73% |
| 2014 Q2 | 239.01 Million TWD | -14.59% |
| 2014 Q3 | 231.77 Million TWD | -3.03% |
| 2014 Q4 | 246.05 Million TWD | 6.16% |
| 2014 Q1 | 279.86 Million TWD | -15.89% |
| 2014 FY | 246.05 Million TWD | -26.05% |
| 2013 FY | 332.71 Million TWD | -7.87% |
| 2013 Q1 | - TWD | -100.0% |
| 2013 Q2 | 276.66 Million TWD | 0.0% |
| 2013 Q3 | 302.78 Million TWD | 9.44% |
| 2013 Q4 | 332.71 Million TWD | 9.88% |
| 2012 Q4 | 361.14 Million TWD | 0.0% |
| 2012 FY | 361.14 Million TWD | 271.12% |
| 2011 FY | 97.31 Million TWD | -98.2% |
| 2010 FY | 5.4 Billion TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| SYN-TECH Chem. & Pharm. Co., Ltd. | 583.48 Million TWD | 80.987% |
| Level Biotechnology Inc. | 273.2 Million TWD | 59.393% |
| Sagittarius Life Science Corp | 137.82 Million TWD | 19.506% |
| NeoCore Technology Co., Ltd. | 197.47 Million TWD | 43.82% |
| TaiMed Biologics Inc. | 1.32 Billion TWD | 91.645% |
| GlycoNex Incorporation | 276.39 Million TWD | 59.862% |
| VBI | 21.25 Million TWD | -422.046% |
| GeneReach Biotechnology Corp. | 313.7 Million TWD | 64.636% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 514.65 Million TWD | 78.444% |
| Visgeneer Inc. | 185.6 Million TWD | 40.228% |
| Mycenax Biotech Inc. | 1.32 Billion TWD | 91.616% |
| Sunmax Biotechnology Co., Ltd. | 732.98 Million TWD | 84.865% |
| G&E Herbal Biotechnology Co., Ltd. | 119.86 Million TWD | 7.442% |
| Medigen Vaccine Biologics Corporation | 2.24 Billion TWD | 95.061% |
| TaiwanJ Pharmaceuticals Co., Ltd. | 6.61 Million TWD | -1576.337% |
| Enimmune corporation | 173.46 Million TWD | 36.044% |
| TaiRx, Inc. | 60.62 Million TWD | -82.994% |
| CHO Pharma, Inc. | 110.83 Million TWD | -0.097% |
| EirGenix Inc. | 1.14 Billion TWD | 90.312% |
| BioLASCO Taiwan Co., Ltd. | 111.98 Million TWD | 0.93% |
| Sunny Pharmtech Inc. | 512.43 Million TWD | 78.351% |
| Lin BioScience, Inc. | 167.73 Million TWD | 33.858% |
| BioGend Therapeutics Co., Ltd. | 93.71 Million TWD | -18.381% |
| Feng Chi Biotech Corp. | 63.03 Million TWD | -76.0% |
| Bio Preventive Medicine Corp. | 124.72 Million TWD | 11.055% |
| Lukas Biomedical Inc. | 161.05 Million TWD | 31.118% |
| RBC Bioscience Corporation | 513.08 Million TWD | 78.378% |
| BiOptic Inc. | 170.56 Million TWD | 34.957% |
| BRIM Biotechnology, Inc. | 42.15 Million TWD | -163.153% |
| Shine-On BioMedical Co.,Ltd. | 23.25 Million TWD | -377.059% |
| Great Novel Therapeutics Biotech & Medicals | 26.81 Million TWD | -313.755% |
| Syngen Biotech Co.,Ltd. | 974.63 Million TWD | 88.617% |
| Anti-Microbial Savior BioteQ Co., Ltd | 6.99 Million TWD | -1486.217% |
| SynCore Biotechnology Co.,Ltd | 21.22 Million TWD | -422.661% |
| Genomics BioSci & Tech. Co.,Ltd. | 368.33 Million TWD | 69.88% |
| Neith Corporation | 17.43 Million TWD | -536.379% |
| Advagene Biopharma Co., Ltd. | 7.97 Million TWD | -1291.621% |
| NaviFUS Corp. | 53.4 Million TWD | -107.749% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 481.48 Million TWD | 76.959% |
| Sinew Pharma Inc. | 39.71 Million TWD | -179.347% |
| Andros Pharmaceuticals Co.,Ltd | 58.03 Million TWD | -91.147% |
| Greenyn Biotechnology Co., Ltd | 364.47 Million TWD | 69.562% |
| Lumosa Therapeutics Co., Ltd. | 227.69 Million TWD | 51.277% |
| AP Biosciences Inc | 106.65 Million TWD | -4.023% |
| Medigen Biotechnology Corp. | 3.53 Billion TWD | 96.857% |
| 3D Global Biotech Inc. | 30.68 Million TWD | -261.592% |
| Pharmosa Biopharm Inc. | 195.99 Million TWD | 43.395% |
| Intech Biopharm Corporation | 1.54 Billion TWD | 92.811% |
| Oneness Biotech Co., Ltd. | 866.42 Million TWD | 87.196% |
| Eusol Biotech Co.,Ltd. | 9.27 Million TWD | -1095.99% |
| TWi Biotechnology, Inc. | 55.81 Million TWD | -98.771% |
| Ever Supreme Bio Technology Co., Ltd | 232.95 Million TWD | 52.378% |
| TCI GENE Inc. | 155.54 Million TWD | 28.678% |
| MegaPro Biomedical Co., Ltd | 25.5 Million TWD | -334.922% |
| Senhwa Biosciences, Inc. | 46.17 Million TWD | -140.26% |
| Taiwan Bio Therapeutics Co., Ltd | 328.47 Million TWD | 66.225% |
| NatureWise Biotech & Medicals Corporation | 64.88 Million TWD | -70.974% |
| PharmaEngine, Inc. | 91 Million TWD | -21.904% |
| Savior Lifetec Corporation | 457.95 Million TWD | 75.775% |
| OBI Pharma, Inc. | 650.44 Million TWD | 82.944% |
| Meribank Biotech Co., Ltd | 390.81 Million TWD | 71.613% |
| Acepodia, Inc. | 384.47 Million TWD | 71.145% |
| Caliway Biopharmaceuticals Co., Ltd. | 85.55 Million TWD | -29.674% |